Literature DB >> 35094291

Treatment Strategy for Oligometastatic Gastric Cancer: Brief Considerations.

Daniele Lavacchi1, Elisa Giommoni1, Fabio Cianchi2,3, Lorenzo Antonuzzo4,5.   

Abstract

Entities:  

Year:  2022        PMID: 35094291     DOI: 10.1007/s12029-021-00792-x

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  13 in total

1.  Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world.

Authors:  Valentina Fanotto; Stefano Cordio; Giulia Pasquini; Caterina Fontanella; Lorenza Rimassa; Francesco Leone; Gerardo Rosati; Daniele Santini; Riccardo Giampieri; Samantha Di Donato; Gianluca Tomasello; Nicola Silvestris; Filippo Pietrantonio; Francesca Battaglin; Antonio Avallone; Mario Scartozzi; Eufemia Stefania Lutrino; Davide Melisi; Lorenzo Antonuzzo; Antonio Pellegrino; Valter Torri; Giuseppe Aprile
Journal:  Gastric Cancer       Date:  2016-12-27       Impact factor: 7.370

2.  Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry.

Authors:  Alberto Carmona-Bayonas; Paula Jiménez-Fonseca; Isabel Echavarria; Manuel Sánchez Cánovas; Gema Aguado; Javier Gallego; Ana Custodio; Raquel Hernández; Antonio Viudez; Juana María Cano; Eva Martínez de Castro; Ismael Macías; Alfonso Martín Carnicero; Marcelo Garrido; Monserrat Mangas; Felipe Álvarez Manceñido; Laura Visa; Aitor Azkarate; Avinash Ramchandani; Ana Fernández Montes; Federico Longo; Ana Sánchez; Paola Pimentel; María Luisa Limón; David Arias; Diego Cacho Lavin; Rodrigo Sánchez Bayona; Paula Cerdá; Pilar García Alfonso
Journal:  Eur J Surg Oncol       Date:  2018-03-31       Impact factor: 4.424

3.  Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.

Authors:  Salah-Eddin Al-Batran; Nils Homann; Claudia Pauligk; Thorsten O Goetze; Johannes Meiler; Stefan Kasper; Hans-Georg Kopp; Frank Mayer; Georg Martin Haag; Kim Luley; Udo Lindig; Wolff Schmiegel; Michael Pohl; Jan Stoehlmacher; Gunnar Folprecht; Stephan Probst; Nicole Prasnikar; Wolfgang Fischbach; Rolf Mahlberg; Jörg Trojan; Michael Koenigsmann; Uwe M Martens; Peter Thuss-Patience; Matthias Egger; Andreas Block; Volker Heinemann; Gerald Illerhaus; Markus Moehler; Michael Schenk; Frank Kullmann; Dirk M Behringer; Michael Heike; Daniel Pink; Christian Teschendorf; Carmen Löhr; Helga Bernhard; Gunter Schuch; Volker Rethwisch; Ludwig Fischer von Weikersthal; Jörg T Hartmann; Michael Kneba; Severin Daum; Karsten Schulmann; Jörg Weniger; Sebastian Belle; Timo Gaiser; Fuat S Oduncu; Martina Güntner; Wael Hozaeel; Alexander Reichart; Elke Jäger; Thomas Kraus; Stefan Mönig; Wolf O Bechstein; Martin Schuler; Harald Schmalenberg; Ralf D Hofheinz
Journal:  Lancet       Date:  2019-04-11       Impact factor: 79.321

4.  Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.

Authors:  Kohei Shitara; Yung-Jue Bang; Satoru Iwasa; Naotoshi Sugimoto; Min-Hee Ryu; Daisuke Sakai; Hyun-Cheol Chung; Hisato Kawakami; Hiroshi Yabusaki; Jeeyun Lee; Kaku Saito; Yoshinori Kawaguchi; Takahiro Kamio; Akihito Kojima; Masahiro Sugihara; Kensei Yamaguchi
Journal:  N Engl J Med       Date:  2020-05-29       Impact factor: 91.245

Review 5.  Oligometastatic gastric cancer: An emerging clinical entity with distinct therapeutic implications.

Authors:  Massimiliano Salati; Nicola Valeri; Andrea Spallanzani; Chiara Braconi; Stefano Cascinu
Journal:  Eur J Surg Oncol       Date:  2018-11-10       Impact factor: 4.424

Review 6.  TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination.

Authors:  Giandomenico Roviello; Sara Fancelli; Marta Rita Gatta Michelet; Giuseppe Aprile; Stefania Nobili; Franco Roviello; Fabio Cianchi; Enrico Mini; Daniele Lavacchi
Journal:  Crit Rev Oncol Hematol       Date:  2020-05-21       Impact factor: 6.312

7.  Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.

Authors:  Salah-Eddin Al-Batran; Nils Homann; Claudia Pauligk; Gerald Illerhaus; Uwe M Martens; Jan Stoehlmacher; Harald Schmalenberg; Kim B Luley; Nicole Prasnikar; Matthias Egger; Stephan Probst; Helmut Messmann; Markus Moehler; Wolfgang Fischbach; Jörg T Hartmann; Frank Mayer; Heinz-Gert Höffkes; Michael Koenigsmann; Dirk Arnold; Thomas W Kraus; Kersten Grimm; Stefan Berkhoff; Stefan Post; Elke Jäger; Wolf Bechstein; Ulrich Ronellenfitsch; Stefan Mönig; Ralf D Hofheinz
Journal:  JAMA Oncol       Date:  2017-09-01       Impact factor: 31.777

8.  First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.

Authors:  Yelena Y Janjigian; Kohei Shitara; Markus Moehler; Marcelo Garrido; Pamela Salman; Lin Shen; Lucjan Wyrwicz; Kensei Yamaguchi; Tomasz Skoczylas; Arinilda Campos Bragagnoli; Tianshu Liu; Michael Schenker; Patricio Yanez; Mustapha Tehfe; Ruben Kowalyszyn; Michalis V Karamouzis; Ricardo Bruges; Thomas Zander; Roberto Pazo-Cid; Erika Hitre; Kynan Feeney; James M Cleary; Valerie Poulart; Dana Cullen; Ming Lei; Hong Xiao; Kaoru Kondo; Mingshun Li; Jaffer A Ajani
Journal:  Lancet       Date:  2021-06-05       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.